The startup's technology, which it plans to launch through an early-access program this summer, is based on a cell fixing and combinatorial barcoding strategy.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.
